VolitionRX | VNRX | Long at $0.54***Stay away if you are risk averse (small cap with 300-400k daily volume and could go to $0).
VolitionRX AMEX:VNRX is a U.S.-based, multinational epigenetics company focused on developing blood tests for early disease detection, primarily targeting cancer and sepsis. Its Nu.Q blood tests are primarily for humans, focusing on early detection of diseases like cancer and sepsis. However, the company has also explored veterinary applications through its Nu.Q Vet product line, targeting cancer screening in animals, particularly dogs.
Recent insider purchases got my attention, with the CEO and Director each grabbing $100k worth at $0.55. Plus, many other insiders have recently been awarded options. The company is making progress in signing multiple licensing deals for their Nu.Q platform in the human market, with strong interest from large companies. Many development milestones have been made within their cancer testing program and more are likely to be announced. However, the company is unprofitable at this time, and this is a highly risky / speculative play. It may take years to unfold or be a total disaster and go to $0.00.
Rolling the dice at $0.54 with the goal to reach $0.75 and $1.00 in the coming 1-2 years. Analyst targets are in the $3.00-$3.50 range.
